A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Trial Profile

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs CK 301 (Primary)
  • Indications Head and neck cancer; Hodgkin's disease; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Checkpoint Therapeutics
  • Most Recent Events

    • 16 Jul 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
    • 21 Mar 2018 According to a Checkpoint Therapeutics media release, company is expecting initial data from this expansion cohort in the second half of 2018.
    • 21 Mar 2018 According to a Checkpoint Therapeutics media release, company has completed the dose escalation portion of the trial and the initiation of the first dose expansion cohort, which is evaluating an 800 mg dose of CK-301 administered every two weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top